Chugai Pharma

Focus: Chugai Pharma is a Tokyo-headquartered pharmaceutical company with 5,000+ employees focused on small-molecule drug development across oncology, immunology, nephrology, rare diseases, and gastroenterology. The company maintains a clinically active pipeline with multiple programs in Phase 3 development.

Oncology Immunology Nephrology Rare Diseases

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Employees

5000+

Open Jobs

About Chugai Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Chugai Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptom

Celiac Disease

N/A

Clinical Trials (1)

NCT05686369A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)

N/A

Help build intelligence for Chugai Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong late-stage pipeline with 9 Phase 3 programs across high-value therapeutic areas including oncology and rare diseases
Established 5,000+ employee base provides stability and infrastructure for career development
Focus on small-molecule innovation across immunology and nephrology offers technical depth for drug discovery and development professionals

Watch Out For

No active job openings reported (activeJobCount: 0) signals limited current hiring despite pipeline activity
Missing financial data (revenue, R&D spend, cash position) prevents assessment of company health and investment capacity
Founded 2023 designation raises questions about organizational structure, stability, and track record

Generated by Claude from Chugai Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MRA

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT00144573Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment

N/A

The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combi

Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT04818983The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

N/A

endoscopy

Chronic Kidney Diseases

N/A

Clinical Trials (1)

NCT02539680Intestinal Phosphate Transporter Expression in CKD Patients

N/A

Patient Reported Outcomes Registry in Patient With Cancer Cachexia

Metastatic Pancreatic Cancer

N/A

Clinical Trials (1)

NCT02983500Patient Reported Outcomes Registry in Patient With Cancer Cachexia

N/A

Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TA

Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT04501497Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

N/A

Eldecalcitol soft capsules

Postmenopausal Osteoporosis

N/A

Clinical Trials (1)

NCT05433207Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis

N/A

Comorbidities treatment

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT01315652Interest of a Standardized Monitoring of Rheumatoid Arthritis: The COMEDRA Trial

N/A

Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment

Lymphoma

N/A

Spectra Optia® IDL-Set

Healthy Allogeneic Donors

N/A

Clinical Trials (1)

NCT01901458Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®

N/A

no interventions

Severe Hemophilia A

N/A

Clinical Trials (1)

NCT05802836Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

N/A

Erlotinib

Non Small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT00418704Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)

N/A

An Observational Study of Patients With Endometriosis to Evaluate the Usefulness of the MEDL Score,

Endometriosis

N/A

Clinical Trials (1)

NCT04846582An Observational Study of Patients With Endometriosis to Evaluate the Usefulness of the MEDL Score, a New Method for Evaluating Endometriosis Using MRI

N/A

Qualitative Interview

Hemophilia A With Inhibitor

N/A

Clinical Trials (1)

NCT04723693An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families

N/A

Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthrit

Rheumatoid Arthritis

N/A

A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)

Non-small-Cell Lung Cancer

N/A

Clinical Trials (1)

NCT03645330A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)

N/A

Objective Pain Measurement Using a Wearable Biosensor and a Mobile Platform in Patients With Endomet

Endometriosis

N/A

Clinical Trials (1)

NCT04318275Objective Pain Measurement Using a Wearable Biosensor and a Mobile Platform in Patients With Endometriosis

N/A

Assessment of Giant Cell Arteritis Medical Practices in France

Giant Cell Arteritis

N/A

Clinical Trials (1)

NCT03658889Assessment of Giant Cell Arteritis Medical Practices in France

N/A

Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency

Rheumatoid Arthritis

N/A

Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in R

Arthritis, Rheumatoid

N/A

Clinical Trials (1)

NCT02569736Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation

N/A

A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT00661284A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)

N/A

Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Ca

Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT02968979Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.

N/A

MRA

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT00144560Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)

N/A

Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Synd

Down Syndrome

N/A

Clinical Trials (1)

NCT02431117Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30

N/A

PD-L1 Expression in Japanese Renal Cell Carcinoma Patients

Renal Cell Carcinoma

N/A

Clinical Trials (1)

NCT03748901PD-L1 Expression in Japanese Renal Cell Carcinoma Patients

N/A

PCO371

Hypoparathyroidism

PHASE_1

Clinical Trials (1)

NCT04209179A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

Phase 1

ROSE12

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT05907980A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Phase 1

AUBE00

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT07030959Study of AUBE00 in Patients With Solid Tumors

Phase 1

DONQ52

Celiac Disease

PHASE_1

Clinical Trials (1)

NCT05425446Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

Phase 1

PCO371

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04649216Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371

Phase 1

VS-6766

Solid Tumours

PHASE_1

Clinical Trials (1)

NCT02407509Phase I Trial of VS-6766 Alone and in Combination With Everolimus

Phase 1

SAIL66

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT05735366A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

Phase 1

RO7496353

Non-small Cell Lung Cancer

PHASE_1

RO5126766

Advanced Non-small Cell Lung Cancer

PHASE_1

Clinical Trials (1)

NCT03681483RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

Phase 1

EOS789

Hyperphosphatemia

PHASE_1

Clinical Trials (1)

NCT02965053A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Phase 1

ERY974

Hepatocellular Carcinoma (HCC)

PHASE_1

Clinical Trials (1)

NCT05022927A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Phase 1

SPYK04

Locally Advanced or Metastatic Solid Tumors

PHASE_1

Clinical Trials (1)

NCT04511845A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Phase 1

RAY121

Antiphospholipid Syndrome (APS)

PHASE_1

Clinical Trials (1)

NCT06723106Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

Phase 1

ALPS12

Extensive Stage Small Cell Lung Cancer

PHASE_1

Clinical Trials (1)

NCT07107490A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Phase 1

LUNA18

Locally Advanced or Metastatic Solid Tumors

PHASE_1

Clinical Trials (1)

NCT05012618A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Phase 1

GC33

Advanced or Metastatic HCC

PHASE_1

Clinical Trials (1)

NCT00746317A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Phase 1

Codrituzumab

Primary Extra-cranial Solid Tumor

PHASE_1

Clinical Trials (1)

NCT04928677A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Phase 1

ERY974

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT02748837A Study of ERY974 in Patient With Advanced Solid Tumors

Phase 1

GYM329

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04708847A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer